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Epstein-Barr virus oropharyngeal shedding has been demonstrated in infectious mono-
nucleosis patients many months after acute illness and long after the disease hallmarks,
atypical lymphocytes and heterophile antibody, have disappeared. Extracellular virus is pres-
ent more frequently in saliva than in other oropharyngeal samples. Prolonged excretion of
EBV in asymptomatic carriers explains the difficulty in tracing case-to-case spread and in-
creased transmissibility in age groups in which salivary exchange is high.
Epidemiological thinking about infectious mononucleosis (IM) has undergone ex-
tensive revision in a relatively short period of time. Since 1968 when Epstein-Barr
virus (EBV) antibody responses during the disease were first demonstrated, a surge
of information has established the etiologic role of EBV [1,2]. Data supporting the
causal relationship have been derived from multiple lines of investigation utilizing
serologic, virologic, and immunologic techniques: (1) EBV antibodies measured by
immunofluorescence, complement fixation, and neutralization are regularly absent
before infectious mononucleosis, appear during the course ofillness, and persist for
years thereafter; (2) specific antibodies ofthe immunoglobulin M type are detectable
early in illness, indicating a primary infection; (3) EBV can be recovered from
leukocyte cultures of IM patients; (4) the presence or absence ofEBV antibodies cor-
relates with resistance or susceptibility to infectious mononucleosis; (5) the classic
heterophile antibody of IM develops in squirrel monkeys inoculated with EBV-
transformed leukocytes; and (6) oropharyngeal excretion of EBV has been
demonstrated in infectious mononucleosis patients.
Elucidation of the behavior of IM in different environmental and sociologic con-
ditions has evolved to a large extent through sero-epidemiologic studies of EBV an-
tibody. Such investigations have shown that the virus is a common and widely
disseminated agent throughout the world and that the majority of EBV infections
are subclinical and inapparent. Infectious mononucleosis is a well-recognized
disorder in populations with advanced sociohygienic standards; here, the peak in-
cidence of disease occurs in adolescents and young adults. Conversely, the disease is
a rarity in crowded, densely populated, developing regions with lower standards of
hygiene.
Because antibody to the viral capsid antigen (VCA) of EBV persists for many
years, probably for life, measurements ofthis IgG antibody in any age group define
cumulative prevalence rates of all persons having previous or current infections and
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associated immunity [3,4]. For example, investigations utilizing this marker have
demonstrated extremely early acquisition of primary EBV infection in African and
Melanesian populations. Biggar et al. studying newborn children in Accra, Ghana,
found that by the age of 18 months 82 percent had been infected [5]. In three
remote, genetically distinct Melanesian populations 89 percent of two-year-old in-
fants were seropositive for EBV. Lang et al. describe the intense interpersonal con-
tact and primitive personal hygiene of these social groups which provide an op-
timum setting for early acquisition and spread of EBV infection [6].
In contrast, Henle and Henle found that, in the Cleveland Family Study,
representing closed western society nuclear groups, the majority of children had
escaped EBV infection up to the age of ten years. Evidence of spread was found in
approximately one-third of family groups, but transmission from parents to
children was not a regular event. Likewise, spread of the virus among siblings was
infrequent, neither from older to younger children, nor vice versa [7]. Joncas and
Mitnyan followed 67 EBV-antibody negative members of 75 Canadian families over
a period of approximately two years; only 10.5 percent of these susceptibles
developed asymptomatic seroconversion [8].
Investigations of college and military populations have repeatedly demonstrated
the low contagiousness of infectious mononucleosis to susceptible and exposed
roommates of index IM cases [3,4,9,10]. Prospective studies of university students
in the United States and Great Britain indicate EBV infection rates of only 12-13
percent per year among susceptibles. In recent work at Yale University, 18 antibody-
negative roommates or close contacts of 17 IM patients were observed over a period
of nine months [11]. In this group only one contact developed clinical illness
associated with elevated heterophile antibody 41 days after exposure. No clinical
symptoms of mononucleosis or evidence of EBV seroconversion occurred in the
other 17 subjects. The secondary attack rate of one of 18 roommates (5.5 percent)
was lower than the overall university EBV infection rate of 13.1 percent.
In studies of other age groups, sera from six-year-old school children entering
grammar schools located in upper and lower socioeconomic districts in New Haven,
Connecticut, were tested for EBV antibody prevalence and compared to matched
samples collected four years later. The EBV seroconversion rate was 50 percent in
children from less economically privileged areas and only 2.4 percent in the more ad-
vantaged groups. Taken together, such serologic results, demonstrating early ac-
quisition of subclinical EBV infection in infants from developing countries, in
children from lower socioeconomic sectors of developed regions, and in nurseries
and institutions, indicate that close personal contact is a common denominator for
circulation of EB virus in young age groups. These findings contrast with the low
contagiousness of adults with clinical infectious mononucleosis and scant evidence
that the disorder occurs in epidemic form.
Unlike some contact diseases, such as measles and rubella, in which the disease
passes from one recognized case to another, it has been difficult to trace transmis-
sion of infectious mononucleosis on a case-to-case basis. Numerous efforts, under-
taken as early as 1937, to identify the etiology and to transmit IM were made by
many investigators. In such attempts utilizing different routes of administration, 91
volunteers received inocula including blood, serum, throat and nasal washings,
lymph node suspensions, and stool suspensions obtained from acutely ill patients.
The results were unsuccessful and inconclusive except for one trial, reported by Wis-
ing in 1942. In this investigation the disease was transmitted to a 23-year-old female
volunteer who received 250 ml of heparinized whole blood obtained from a 31-year-
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old donor during the first week of clinical infectious mononucleosis. Approximately
three weeks following transfusion, the recipient developed full-blown clinical disease
together with heterophile antibody production [121.
Identification of the etiologic role of Epstein-Barr virus promptly opened the way
for studies of factors involved in transmission of IM. The role of the oropharynx as
a dominant route of transmission had been suggested earlier by Hoagland's observa-
tions which raised the possibility of actively infectious saliva; these studies also in-
dicated the existence of a long incubation period of 34-49 days [13]. An essential
step for investigations of such EBV transmission was the development of a sensitive
marker for detection of virus in oropharyngeal secretions. The assay was based on
the unique property of EBV to transform or immortalize primary cultures of fetal
leukocytes. Proof that the transforming agent, detected in throat washings from IM
patients, was EBV included (1) virus-specific complement fixation antigens appeared
in transformed fetal leukocytes, and (2) the transforming activity of the throat
washings was neutralized by antibody to EBV. Furthermore, when the same throat
washings, capable of inducing only complement fixation antigen in umbilical cord
leukocytes, were added to adult human or marmoset leukocytes, the transformants
contained both immune fluorescent and complement-fixing antigens [14,15,16].
Thus, EBV expressions differed in the transformants of different types of cells.
Electron microscopic studies of concentrated throat washings helped to elucidate
the physical nature of the leukocyte-transforming factor [17,18]. Enveloped herpes
virus was observed in concentrated, throat-washing material, obtained from an EBV
antibody-positive patient receiving immunosuppressive therapy for prevention of
renal transplant rejection. On examination, ten virions were 'Observed in a small
drop of the final preparation and the concentrated specimen contained approx-
imately 3 x 108 virions/ml. Transforming activity of the throat washing with viral
particles was neutralized only by EBV antibody-positive sera, and no other human
herpes viruses were present in the specimen. The findings provided direct evidence
that the leukocyte-transforming factor in oropharyngeal specimens is EBV, and
clearly supported the concept that mature enveloped EBV is released by some cell in
the oropharynx.
Other investigations have approached questions regarding viral persistence and
sites of oropharyngeal production in several ways: (1) a group of IM patients was
studied serially to determine whether oropharyngeal excretion was continuous or in-
termittent, (2) throat washings were examined by procedures to determine whether
virus excretion was "cell-associated" or "cell-free," and (3) specimens were collected
from multiple oropharyngeal sites in attempts to localize the sites of virus produc-
tion.
Three general patterns of EBV oropharyngeal excretion were observed in studies
of 104 serial throat washings collected from 20 IM cases. Three (15 percent) patients
shed virus continuously, beginning in the second week through the third month after
onset. The majority (75 percent) excreted virus intermittently throughout the first
three months and as long as 18 months after acute illness. Conversely, serial throat
washings from two other IM patients lacked detectable virus in all specimens.
Techniques eliminating infected cells in throat washings did not alter their capacity
for transformation and indicated that EBV is located extracellularly in the oro-
pharynx. A small amount of virus was commonly present in saliva and also detected
in fluids collected by swabbing multiple sites of the oropharynx, including the
orifices of Stensen's ducts. Such findings implicated the salivary glands as one
potential site of EBV production and suggested that virus is released by a cell in
261JAMES C. NIEDERMAN
salivary glands, perhaps ductal or glandular epithelium or by specialized lymphoid
cells [19]. Demonstration of the presence of EBV-DNA in exfoliated buccal mucosa
cells by in situ nucleic acid hybridization techniques suggests that epithelial cells of
the buccal mucosa may also be a source of EBV [20].
In other investigations of viral shedding, cells and cell-free parotid secretions,
saliva, and throat washings from young adult patients with acute IM and patients of
similar age undergoing tonsillectomy were assayed for the presence of infectious EB
virus. From 21 patients undergoing tonsillectomy, secretions were obtained by can-
nulation of the parotid ducts; in a group of 19 IM patients, saliva was aspirated
from the orifice of Stensen's duct. Seventeen of 21 patients from whom samples
were obtained by cannulation were seropositive for EBV; infectious EBV was found
in specimens from two of these subjects. In one tonsillectomy case who had IM two
and a half months previously, saliva from both parotid ducts contained EBV; the
virus was also present in saliva cannulated from the right parotid gland of another
seropositive patient without a history of IM. Oral saliva from both subjects con-
tained EBV; in one case, more virus was present in the cannulated specimen than in
the oral sample. EBV was not recovered from extracts oftonsil lymphocytes ofeight
subjects, including both individuals whose parotid ducts yielded virus. Saliva
aspirated from the orifice of Stensen's duct contained EBV in eight of 19 patients
with acute IM, and all had detectable virus in oral salivary specimens [21].
Taken together, these findings indicate that the salivary glands are a major site of
oropharyngeal production of Epstein-Barr virus and shed light on transmission of
the infection. Such low-level, long-term EBV production in salivary glands may
stimulate life-long maintenance of viral capsid antigen, membrane antigen, and
specific nuclear antigens. From a theoretical standpoint, it is also possible that
primary EBV replication takes place in the salivary gland before B lymphocytes are
infected and some individuals may have only salivary gland infection in the absence
of leukoviremia.
Person-to-person transmission of viral infection is influenced by both the pattern
and sites of excretion of the agent. To a large extent, contagiousness correlates with
the titers of virus excreted; patients who shed large amounts of virus are likely to be
highly infectious. For example, in diseases like measles and influenza, characterized
by rapid spread and explosive epidemics, large amounts of virus are excreted by pa-
tients for brief periods of several days. In the case of respiratory syncytial virus in-
fections, more than 100,000 infectious units per milliliter of nasopharyngeal
washings are present for two to three weeks after onset; thus, the virus is highly con-
tagious and outbreaks may last several months.
In the case of infectious mononucleosis, identification of asymptomatic oropha-
ryngeal excretion and the prolonged carrier state ofEBV following clinical illness ex-
plains a number of questions about its transmissibility and the difficulty in tracing
case-to-case spread. In age groups in which salivary exchange is high, transmissibil-
ity is high and conversely is low in groups where this type of contact is uncommon.
Other sites of EBV production and excretion have not yet been identified, and
virus has not been recovered from urine, feces, and cervical secretions [22]. How-
ever, longitudinal studies similar to those ofBuddingh et al. which demonstrated in-
termittent appearance of herpes-simplex virus in the feces of human carriers need to
be carried out [23]. latrogenic sources of primary infection have also been recog-
nized; transfusion of fresh whole blood, plasma, or packed red blood cells, and
transplantation of bone marrow entail risk of infection to the susceptible recipient
[24,25,26].
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Important information is now emerging on shedding of the virus in im-
munologically altered hosts. Strauch et al. studied oropharyngeal EBV excretion in
80 patients from a hospital renal disease unit [27]. In antibody-positive renal
transplant recipients treated with immunosuppressive agents the rate of excretion
was 52 percent. In eight older seropositive individuals receiving renal homografts
none were excreting EB virus in single oropharyngeal samples before transplanta-
tion; two were shedding virus 8 and 34 days after transplantation and institution of
therapy. EB virus excretion in immunosuppressed patients presumably results from
reactivation and release of endogenous virus remaining from previous infections. In
such patients the shift fron non-productive to productive infection occurs in the
presence of circulating antibody indicating that humoral antibody does not exert a
regulatory role in oropharyngeal excretion and that immunosuppressive drugs may
affect cell-mediated immune mechanisms. An alternative hypothesis is that such
drugs act directly on oropharyngeal cells which carry the agent and cause the virus to
be reactivated.
The association of immunosuppressive drugs with reactivation of latent EB virus
infections provides important biologic clues concerning mechanisms of asymp-
tomatic excretion of EB virus in the general population, whereby a reservoir of
transmissible virus is maintained. In regard to transmission of EBV infection, we
know that once primary infection has occurred the individual carries EBV for life.
Small amounts of virus are present in the saliva of approximately 20 percent of
healthy seropositive subjects, and virus-neutralizing, VCA, and EBNA antibodies
persist indefinitely. However, a much clearer understanding at a molecular level is
needed of the events involved in EB virus production and release in the oropharynx
and perhaps elsewhere. Such complex viral-host arabesques provide challenging
areas of investigation involving virologic, immunologic, and genetic techniques which
may well enlarge the spectrum of EBV-associated syndromes.
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